Clinical Trials Directory

Trials / Conditions / IPF

IPF

36 registered clinical trials studyying IPF11 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safet
NCT07519070
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Not Yet RecruitingA Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation
NCT07528703
Nanjing Reju Therapeutics Co., LtdPhase 1
Not Yet RecruitingA PhaseⅠ Study of HW252001 in Healthy Subjects
NCT07493031
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Phase 1
RecruitingA Phase Ia Clinical Trial of HW241045
NCT07448194
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Phase 1
RecruitingSB17170 Phase 2 Trial in IPF Patients
NCT06747923
SPARK BiopharmaPhase 2
Active Not RecruitingAssessment of Self-Care in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07139925
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RecruitingP4O2 ILD Extension
NCT06644144
Amsterdam UMC, location VUmc
CompletedBiomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
NCT06331624
GRI Bio Operations, Inc.Phase 2
CompletedA Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Sa
NCT06310746
Shanghai Henlius BiotechPhase 1
Active Not RecruitingEfficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-I
NCT05983471
Melius Pharma ABPhase 2
RecruitingPhase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants W
NCT06181370
Agomab Spain S.L.Phase 1
CompletedApplication of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis
NCT06714188
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Active Not RecruitingDiarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Ni
NCT06714812
IRCCS Azienda Ospedaliero-Universitaria di Bologna
CompletedA Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
NCT05895565
Pulmongene Ltd.Phase 1
CompletedA Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
NCT05803850
Guangzhou Henovcom Bioscience Co. Ltd.Phase 1
WithdrawnA Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
NCT05349760
AmMax Bio, Inc.Phase 2
CompletedPrognostic Score Comparison in IPF and HP
NCT07169253
Saglik Bilimleri Universitesi
Active Not RecruitingAssess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary
NCT05570058
Redx Pharma LtdPhase 2
CompletedEffects of Home-based Inspiratory Muscle Training in Patients With IPF
NCT05353556
Dokuz Eylul UniversityN/A
RecruitingTurkish Validity and Reliability of SGRQ-I
NCT05147597
Saglik Bilimleri Universitesi
RecruitingSleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
NCT05193136
National Hospital Organization Minami Kyoto Hospital
RecruitingTelerehabilitation in Patients With Idiopathic Pulmonary Fibrosis
NCT05190211
Istanbul Medipol University HospitalN/A
CompletedILAs in CT Lung Cancer Screening Population
NCT04503044
Lahey Clinic
Active Not RecruitingAdvancing Prevention of Pulmonary Fibrosis
NCT04564183
University of Colorado, Denver
TerminatedA Study of Patients With Chronic Disease
NCT04263727
Target PharmaSolutions, Inc.
TerminatedA Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
NCT03864328
Respivant Sciences GmbHPhase 2
UnknownInhaled NO in IPF and COPD During 6 Minute Walk Test
NCT03873298
Rabin Medical CenterPhase 2
RecruitingThe Role of Laryngopharyngeal Reflux in IPF
NCT03418350
National Jewish Health
CompletedIdiopathic Pulmonary Fibrosis Job Exposures Study
NCT03211507
Imperial College London
UnknownThe Coagulation Cascade in Idiopathic Pulmonary Fibrosis
NCT02885961
University College, LondonN/A
CompletedSafety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis
NCT02503657
MediciNovaPhase 2
UnknownNasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
NCT02807025
Imperial College Healthcare NHS Trust
CompletedFunctional MR Lung Imaging Using Hyperpolarised 129Xe
NCT02976935
University of Nottingham
CompletedProspective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis
NCT02151435
University of Michigan
CompletedThe Effectiveness of Pulmonary Rehabilitation on Saturation in Patients With Idiopathic Pulmonary Fibrosis
NCT07031362
Izmir Katip Celebi UniversityN/A
CompletedCombined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
NCT01266317
Michael DonahoePhase 1 / Phase 2